Opinion: CEO of Mylan Not to Blame for EpiPen Prices; U.S. Healthcare System Is

iStock

Opinion: CEO of Mylan Not to Blame for EpiPen Prices; U.S. Healthcare System Is

Oct, 12th 2016

No, your eyes (or wallet) aren't deceiving you -- the perception of pharmaceutical price-gouging has certainly become more commonplace over the past year.

Last September, Martin Shkreli, the "Bad Boy of Pharma," increased the price of a 62-year-old rare-disease drug known as Daraprim by more than 5,500% overnight for the explicit reasoning of generating more profit for his now-former company, Turing Pharmaceuticals. What made Shkreli's move so brash was that Turing made no changes to the formulation or manufacturing process of Daraprim. It was merely passing along a roughly 5,500% price increase because it could.

Shortly thereafter, it was Valeant Pharmaceuticals' (NYSE:VRX) turn to be raked over the coals for similar pricing practices with cardiovascular medications Nitropress and Isuprel, both of which were acquired by Valeant in Feb. 2015 from...

Read More

Join Us. We are waiting for you!

Sign Up Today!

We welcome you to our community where you can gather and share information on debts and issues which may have your life unsettled. Together we thrive!


Logo mobile 4b2fda9e088d7249be95ede0cc3adea2de299a346ba55b450264e0c976b239c5

Join our community Today! IT'S FREE

Our Interactive Knowledge Base Has All The Infomation You Need To Settle Your Debt & Settle Your Life™

SIGN UP NOW!

Join, Resolve & Share!